联合疗法治疗精神疾病患者的优势
The Advantages of Combining Therapies in Treating Psychiatric Patients.
作者信息
Rajkumar Ravi Philip
机构信息
Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605006, India.
出版信息
Brain Sci. 2024 Jul 15;14(7):708. doi: 10.3390/brainsci14070708.
Abstract
Mental illnesses are among the leading causes of morbidity and disability worldwide, and the burden associated with these disorders has increased steadily over the past three decades [...].
摘要
精神疾病是全球发病和致残的主要原因之一，在过去三十年中，与这些疾病相关的负担一直在稳步增加[……]。
相似文献
1
The Advantages of Combining Therapies in Treating Psychiatric Patients.联合疗法治疗精神疾病患者的优势
Brain Sci. 2024 Jul 15;14(7):708. doi: 10.3390/brainsci14070708.
2
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.2010 年全球疾病负担研究：1990-2010 年 289 种疾病和伤害的 1160 种后遗症导致的残疾生存年数的系统分析。
Lancet. 2012 Dec 15;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2.
3
[The evolution of child psychiatry emergencies: Results and reflections from a Nancy University Hospital study].[儿童精神科急症的演变：南锡大学医院一项研究的结果与思考]
Encephale. 2021 Aug;47(4):348-355. doi: 10.1016/j.encep.2020.08.011. Epub 2021 Jan 14.
4
Psychiatric Disorders Are Associated with an Increased Risk of Injuries: Data from the Iranian Mental Health Survey (IranMHS).精神疾病与受伤风险增加相关：来自伊朗心理健康调查（IranMHS）的数据。
Iran J Public Health. 2016 May;45(5):623-35.
5
The prevalence and burden of mental and substance use disorders in Australia: Findings from the Global Burden of Disease Study 2015.澳大利亚精神和物质使用障碍的流行程度和负担：来自 2015 年全球疾病负担研究的发现。
Aust N Z J Psychiatry. 2018 May;52(5):483-490. doi: 10.1177/0004867417751641. Epub 2018 Jan 11.
6
Functional and psychiatric vestibular disorders.功能性和精神性前庭障碍。
Handb Clin Neurol. 2016;137:341-51. doi: 10.1016/B978-0-444-63437-5.00024-8.
7
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.全球死亡率、残疾率及风险因素的影响：全球疾病负担研究
Lancet. 1997 May 17;349(9063):1436-42. doi: 10.1016/S0140-6736(96)07495-8.
8
Tobacco use treatment in primary care patients with psychiatric illness.对患有精神疾病的初级保健患者进行烟草使用治疗。
J Am Board Fam Med. 2014 May-Jun;27(3):399-410. doi: 10.3122/jabfm.2014.03.130252.
9
Alarming changes in the global burden of mental disorders in children and adolescents from 1990 to 2019: a systematic analysis for the Global Burden of Disease study.令人担忧的变化：1990 年至 2019 年全球儿童和青少年精神障碍负担
Eur Child Adolesc Psychiatry. 2022 Nov;31(11):1827-1845. doi: 10.1007/s00787-022-02040-4. Epub 2022 Jul 14.
10
Analysis of inpatient cost burden and influencing factors of seniors' patients with mental illness in Dalian, China.中国大连老年精神疾病住院患者费用负担及影响因素分析。
BMC Geriatr. 2023 Nov 14;23(1):739. doi: 10.1186/s12877-023-04424-w.
本文引用的文献
1
Efficacy and suitability of adding short-term psychodynamic psychotherapy (STPP) to pharmacotherapy in patients with depressive disorders: a systematic review.在抑郁症患者的药物治疗中添加短期心理动力心理治疗（STPP）的疗效与适用性：一项系统评价
Trends Psychiatry Psychother. 2024 Apr 30. doi: 10.47626/2237-6089-2023-0764.
2
The therapeutic effectiveness of artificial intelligence-based chatbots in alleviation of depressive and anxiety symptoms in short-course treatments: A systematic review and meta-analysis.基于人工智能的聊天机器人在短程治疗中缓解抑郁和焦虑症状的疗效：系统评价和荟萃分析。
J Affect Disord. 2024 Jul 1;356:459-469. doi: 10.1016/j.jad.2024.04.057. Epub 2024 Apr 15.
3
Optimizing precision medicine for second-step depression treatment: a machine learning approach.优化第二步抑郁症治疗的精准医学：一种机器学习方法。
Psychol Med. 2024 Jul;54(10):2361-2368. doi: 10.1017/S0033291724000497. Epub 2024 Mar 27.
4
DRD4 VNTR 4/4 homozygosity as a genetic biomarker for treatment selection in patients with schizophrenia.DRD4 VNTR 4/4 纯合子作为精神分裂症患者治疗选择的遗传生物标志物。
Asian J Psychiatr. 2024 Jan;91:103831. doi: 10.1016/j.ajp.2023.103831. Epub 2023 Nov 7.
5
New trends in personalized treatment of depression.抑郁症个性化治疗的新趋势。
Curr Opin Psychiatry. 2024 Jan 1;37(1):3-8. doi: 10.1097/YCO.0000000000000903. Epub 2023 Oct 19.
6
Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder.右美沙芬-安非他酮（Auvelity）用于治疗重度抑郁症。
Clin Psychopharmacol Neurosci. 2023 Nov 30;21(4):609-616. doi: 10.9758/cpn.23.1081. Epub 2023 Jul 17.
7
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.迷幻蘑菇辅助治疗抑郁症：系统评价和荟萃分析。
Psychiatry Res. 2023 Nov;329:115531. doi: 10.1016/j.psychres.2023.115531. Epub 2023 Oct 11.
8
Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT.基于药物基因组学检测指导的抗抑郁治疗对临床结局的影响：一项 RCT 的系统评价和荟萃分析。
BMC Psychiatry. 2023 May 12;23(1):334. doi: 10.1186/s12888-023-04756-2.
9
Early antidepressant treatment response prediction in major depression using clinical and TPH2 DNA methylation features based on machine learning approaches.基于机器学习方法的临床和 TPH2 DNA 甲基化特征预测重度抑郁症的早期抗抑郁治疗反应。
BMC Psychiatry. 2023 May 1;23(1):299. doi: 10.1186/s12888-023-04791-z.
10
The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.精神障碍新型治疗方法发现的艰难之路。
Adv Neurobiol. 2023;30:255-285. doi: 10.1007/978-3-031-21054-9_11.
Zotero 插件